Since PPAR-β/δ is abundantly expressed in the brain, and both PPAR-β/δ and PPAR-γ [56,57] agonists exhibit therapeutic efficacy in experimental AD models, dual activation of their receptors may provide enhanced therapeutic benefit in humans with AD. The gene discussed is PPARG; the disease is Alzheimer disease.